Genentech terminates migoprotafib collaboration; Relay loses future milestones

Relay Therapeutics, Inc.

Genentech terminated without cause; effective 180 days after July 11, 2024.
Relay had received $121.8M total ($75M upfront + $45M milestones + R&D costs).
No further milestone or royalty payments due after termination date.
Relay regains full rights to migoprotafib (SHP2 inhibitor) and all associated data.
Termination removes expected future payments; drug development status uncertain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.